Chuu Jiunn-Jye, Lu Jeng-Wei, Chang Hung-Ju, Chu You-Hsiang, Peng Yi-Jen, Ho Yi-Jung, Shen Pei-Hung, Cheng Yu-Shuan, Cheng Chia-Hui, Liu Yi-Chien, Wang Chih-Chien
Department of Biotechnology and Food Technology College of Engineering, Southern Taiwan University of Science Tainan Taiwan.
Biotech Research and Innovation Centre University of Copenhagen Copenhagen Denmark.
Food Sci Nutr. 2023 Oct 8;12(1):116-130. doi: 10.1002/fsn3.3746. eCollection 2024 Jan.
Osteoporosis is characterized by low bone mass, bone microarchitecture disruption, and collagen loss, leading to increased fracture risk. In the current study, collagen peptides were extracted from milkfish scales (MS) to develop potential therapeutic candidates for osteoporosis. MS was used to synthesize a crude extract of fish scales (FS), collagen liquid (COL), and hydroxyapatite powder (HA). COL samples were further categorized according to the peptide size of total COL (0.1 mg/mL), COL < 1 kDa (0.1 mg/mL), COL: 1-10 kDa (0.1 mg/mL), and COL > 10 kDa (0.1 mg/mL) to determine it. Semi-quantitative reverse transcription polymerase chain reaction (sqRT-PCR) and immunofluorescence labeling were used to assess the expression levels of specific mRNA and proteins in vitro. For in vivo studies, mice ovariectomy (OVX)-induced postmenopausal osteoporosis were developed, while the sham surgery (Sham) group was treated as a control. Collagen peptides (CP) from MS inhibited osteoclast differentiation in RAW264.7 cells following an insult with nuclear factor kappa-B ligand (RANKL). CP also enhanced osteoblast proliferation in MG-63 cells, possibly through downregulating NFATc1 and TRAP mRNA expression and upregulating ALP and OPG mRNA levels. Furthermore, COL1 kDa also inhibited bone density loss in osteoporotic mice. Taken together, CP may reduce RANKL-induced osteoclast activity while promoting osteoblast synthesis, and therefore may act as a potential therapeutic agent for the prevention and control of osteoporosis.
骨质疏松症的特征是骨量低、骨微结构破坏和胶原蛋白流失,导致骨折风险增加。在本研究中,从虱目鱼鱼鳞(MS)中提取胶原蛋白肽,以开发潜在的骨质疏松症治疗候选物。MS被用于合成鱼鳞粗提物(FS)、胶原蛋白液(COL)和羟基磷灰石粉末(HA)。COL样品根据总COL(0.1 mg/mL)、COL < 1 kDa(0.1 mg/mL)、COL:1 - 10 kDa(0.1 mg/mL)和COL > 10 kDa(0.1 mg/mL)的肽大小进一步分类以进行测定。使用半定量逆转录聚合酶链反应(sqRT-PCR)和免疫荧光标记在体外评估特定mRNA和蛋白质的表达水平。对于体内研究,构建小鼠卵巢切除(OVX)诱导的绝经后骨质疏松症模型,而假手术(Sham)组作为对照。来自MS的胶原蛋白肽(CP)在受到核因子κ-B配体(RANKL)刺激后抑制RAW264.7细胞中的破骨细胞分化。CP还可能通过下调NFATc1和TRAP mRNA表达以及上调ALP和OPG mRNA水平来增强MG-63细胞中的成骨细胞增殖。此外,COL1 kDa还抑制骨质疏松症小鼠的骨密度损失。综上所述,CP可能降低RANKL诱导的破骨细胞活性,同时促进成骨细胞合成,因此可能作为预防和控制骨质疏松症的潜在治疗剂。